|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Nakasone ES, Hurvitz SA and McCann KE:
Harnessing the immune system in the battle against breast cancer.
Drugs Context. 7:2125202018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Balkwill FR: The chemokine system and
cancer. J Pathol. 226:148–157. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zlotnik A, Burkhardt AM and Homey B:
Homeostatic chemokine receptors and organ-specific metastasis. Nat
Rev Immunol. 11:597–606. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhu Q, Han X, Peng J, Qin H and Wang Y:
The role of CXC chemokines and their receptors in the progression
and treatment of tumors. J Mol Histol. 43:699–713. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Vandercappellen J, Van Damme J and Struyf
S: The role of CXC chemokines and their receptors in cancer. Cancer
Lett. 267:226–244. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Holmes WE, Lee J, Kuang WJ, Rice GC and
Wood WI: Structure and functional expression of a human
interleukin-8 receptor. Science. 253:1278–1280. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Murphy PM and Tiffany HL: Cloning of
complementary DNA encoding a functional human interleukin-8
receptor. Science. 253:1280–1283. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kunsch C and Rosen CA: NF-kappa B
subunit-specific regulation of the interleukin-8 promoter. Mol Cell
Biol. 13:6137–6146. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ha H, Debnath B and Neamati N: Role of the
CXCL8-CXCR1/2 axis in cancer and inflammatory diseases.
Theranostics. 7:1543–1588. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tokunaga R, Zhang W, Naseem M, Puccini A,
Berger MD, Soni S, McSkane M, Baba H and Lenz HJ: CXCL9, CXCL10,
CXCL11/CXCR3 axis for immune activation-A target for novel cancer
therapy. Cancer Treat Rev. 63:40–47. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Gupta SK, Lysko PG, Pillarisetti K,
Ohlstein E and Stadel JM: Chemokine receptors in human endothelial
cells. Functional expression of CXCR4 and its transcriptional
regulation by inflammatory cytokines. J Biol Chem. 273:4282–4287.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Coke CJ, Scarlett KA, Chetram MA, Jones
KJ, Sandifer BJ, Davis AS, Marcus AI and Hinton CV: Simultaneous
activation of induced heterodimerization between CXCR4 chemokine
receptor and cannabinoid receptor 2 (CB2) reveals a mechanism for
regulation of tumor progression. J Biol Chem. 291:9991–10005. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Forster R, Mattis AE, Kremmer E, Wolf E,
Brem G and Lipp M: A putative chemokine receptor, BLR1, directs B
cell migration to defined lymphoid organs and specific anatomic
compartments of the spleen. Cell. 87:1037–1047. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Mitkin NA, Hook CD, Schwartz AM, Biswas S,
Kochetkov DV, Muratova AM, Afanasyeva MA, Kravchenko JE,
Bhattacharyya A and Kuprash DV: p53-dependent expression of CXCR5
chemokine receptor in MCF-7 breast cancer cells. Sci Rep.
5:93302015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Szpakowska M, Meyrath M, Reynders N,
Counson M, Hanson J, Steyaert J and Chevigné A: Mutational analysis
of the extracellular disulphide bridges of the atypical chemokine
receptor ACKR3/CXCR7 uncovers multiple binding and activation modes
for its chemokine and endogenous non-chemokine agonists. Biochem
Pharmacol. 153:299–309. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ringner M, Fredlund E, Hakkinen J, Borg A
and Staaf J: GOBO: Gene expression-based outcome for breast cancer
online. PLoS One. 6:e179112011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Goldhirsch A, Winer EP, Coates AS, Gelber
RD, Piccart-Gebhart M, Thurlimann B and Senn HJ; Panel members, :
Personalizing the treatment of women with early breast cancer:
Highlights of the St Gallen international expert consensus on the
primary therapy of early breast cancer 2013. Ann Oncol.
24:2206–2223. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Curtis C, Shah SP, Chin SF, Turashvili G,
Rueda OM, Dunning MJ, Speed D, Lynch AG, Samarajiwa S, Yuan Y, et
al: The genomic and transcriptomic architecture of 2,000 breast
tumours reveals novel subgroups. Nature. 486:346–352. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Finak G, Bertos N, Pepin F, Sadekova S,
Souleimanova M, Zhao H, Chen H, Omeroglu G, Meterissian S, Omeroglu
A, et al: Stromal gene expression predicts clinical outcome in
breast cancer. Nat Med. 14:518–527. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Neve RM, Chin K, Fridlyand J, Yeh J,
Baehner FL, Fevr T, Clark L, Bayani N, Coppe JP, Tong F, et al: A
collection of breast cancer cell lines for the study of
functionally distinct cancer subtypes. Cancer Cell. 10:515–527.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Farmer P, Bonnefoi H, Becette V,
Tubiana-Hulin M, Fumoleau P, Larsimont D, Macgrogan G, Bergh J,
Cameron D, Goldstein D, et al: Identification of molecular apocrine
breast tumours by microarray analysis. Oncogene. 24:4660–4671.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhang M, Liu HX, Teng XD, Wang HB, Cui J,
Jia SS, Gu XY and Li ZG: The differences in CXCR4 protein
expression are significant for the five molecular subtypes of
breast cancer. Ultrastruct Pathol. 36:381–386. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Xu TP, Shen H, Liu LX and Shu YQ: The
impact of chemokine receptor CXCR4 on breast cancer prognosis: A
meta-analysis. Cancer Epidemiol. 37:725–731. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wang F, Li S, Zhao Y, Yang K, Chen M, Niu
H, Yang J, Luo Y, Tang W and Sheng M: Predictive role of the
overexpression for CXCR4, C-Met, and VEGF-C among breast cancer
patients: A meta-analysis. Breast. 28:45–53. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chen HW, Du CW, Wei XL, Khoo US and Zhang
GJ: Cytoplasmic CXCR4 high-expression exhibits distinct poor
clinicopathological characteristics and predicts poor prognosis in
triple-negative breast cancer. Curr Mol Med. 13:410–416. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chu QD, Panu L, Holm NT, Li BD, Johnson LW
and Zhang S: High chemokine receptor CXCR4 level in triple negative
breast cancer specimens predicts poor clinical outcome. J Surg Res.
159:689–695. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Dayer R, Babashah S, Jamshidi S and
Sadeghizadeh M: Upregulation of CXC chemokine receptor 4-CXC
chemokine ligand 12 axis ininvasive breast carcinoma: A potent
biomarker predicting lymph node metastasis. J Cancer Res Ther.
14:345–350. 2018.PubMed/NCBI
|
|
29
|
Lefort S, Thuleau A, Kieffer Y, Sirven P,
Bieche I, Marangoni E, Vincent-Salomon A and Mechta-Grigoriou F:
CXCR4 inhibitors could benefit to HER2 but not to triple-negative
breast cancer patients. Oncogene. 36:1211–1222. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ierano C, Basseville A, To KK, Zhan Z,
Robey RW, Wilkerson J, Bates SE and Scala S: Histone deacetylase
inhibitors induce CXCR4 mRNA but antagonize CXCR4 migration. Cancer
Biol Ther. 14:175–183. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Duffy MJ, Synnott NC and Crown J: Mutant
p53 in breast cancer: Potential as a therapeutic target and
biomarker. Breast Cancer Res Treat. 170:213–219. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Rakha EA, Elsheikh SE, Aleskandarany MA,
Habashi HO, Green AR, Powe DG, El-Sayed ME, Benhasouna A, Brunet
JS, Akslen LA, et al: Triple-negative breast cancer: Distinguishing
between basal and nonbasal subtypes. Clin Cancer Res. 15:2302–2310.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Chen Y, Jacamo R, Konopleva M, Garzon R,
Croce C and Andreeff M: CXCR4 downregulation of let-7a drives
chemoresistance in acute myeloid leukemia. J Clin Invest.
123:2395–2407. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Heckmann D, Maier P, Laufs S, Wenz F,
Zeller WJ, Fruehauf S and Allgayer H: CXCR4 expression and
treatment with SDF-1α or plerixafor modulate proliferation and
chemosensitivity of colon cancer cells. Transl Oncol. 6:124–132.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Liang S, Peng X, Li X, Yang P, Xie L, Li
Y, Du C and Zhang G: Silencing of CXCR4 sensitizes triple-negative
breast cancer cells to cisplatin. Oncotarget. 6:1020–1030. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Yang SX, Loo WT, Chow LW, Yang XH, Zhan Y,
Fan LJ, Zhang F, Chen L, Wang QL, Xiao HL, et al: Decreased
expression of C-erbB-2 and CXCR4 in breast cancer after primary
chemotherapy. J Transl Med. 10 (Suppl 1):S32012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Rhodes LV, Short SP, Neel NF, Salvo VA,
Zhu Y, Elliott S, Wei Y, Yu D, Sun M, Muir SE, et al: Cytokine
receptor CXCR4 mediates estrogen-independent tumorigenesis,
metastasis, and resistance to endocrine therapy in human breast
cancer. Cancer Res. 71:603–613. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Park S, Lee SK, Paik HJ, Ryu JM, Kim I,
Bae SY, Yu J, Kim SW, Lee JE and Nam SJ: Adjuvant endocrine therapy
alone in patients with node-positive, luminal A type breast cancer.
Medicine. 96:e67772017. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Ma B, Khazali A and Wells A: CXCR3 in
carcinoma progression. Histol Histopathol. 30:781–792.
2015.PubMed/NCBI
|
|
40
|
Zhu G, Yan HH, Pang Y, Jian J, Achyut BR,
Liang X, Weiss JM, Wiltrout RH, Hollander MC and Yang L: CXCR3 as a
molecular target in breast cancer metastasis: Inhibition of tumor
cell migration and promotion of host anti-tumor immunity.
Oncotarget. 6:43408–43419. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Oghumu S, Varikuti S, Terrazas C, Kotov D,
Nasser MW, Powell CA, Ganju RK and Satoskar AR: CXCR3 deficiency
enhances tumor progression by promoting macrophage M2 polarization
in a murine breast cancer model. Immunology. 143:109–119. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Bronger H, Karge A, Dreyer T, Zech D,
Kraeft S, Avril S, Kiechle M and Schmitt M: Induction of cathepsin
B by the CXCR3 chemokines CXCL9 and CXCL10 in human breast cancer
cells. Oncol Lett. 13:4224–4230. 2017. View Article : Google Scholar : PubMed/NCBI
|
